isoproterenol and Heart Failure studies

Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research Excerpts

Excerpt	Relevance	Reference
"Myocardial infarction was induced by injecting subcutaneous isoproterenol (5 mg/kg once for 7 consecutive days) to establish an experimental heart failure model."	8.31	Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach. ( Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F, 2023)
" However, the effect and potential mechanism of OMT on isoproterenol (ISO)-induced heart failure (HF) are not clear."	8.31	Oxymatrine attenuated isoproterenol-induced heart failure via the TLR4/NF-κB and MAPK pathways in vivo and in vitro. ( Bai, J; Fu, D; Sun, H; Sun, Y; Wang, Y; Wei, C; Zhen, D, 2023)
" Hemodynamics, lipid profile, liver enzymes, urea, and creatinine were assessed in conjunction with heart failure markers (serum NT-proANP and cTnI)."	8.31	Inhibition of transglutaminase 2 (TG2) ameliorates ventricular fibrosis in isoproterenol-induced heart failure in rats. ( Abusara, S; Al-Dwairi, A; Al-Shboul, O; Al-U'datt, DGF; AlQudah, M; Altuntas, Y; Alu'datt, M; Alzoubi, KH; Hiram, R; Jaradat, S; Tranchant, CC, 2023)
"The effects of recombinant semaphorin 3A (Sema3A) on myocardial contractility and electrical remodeling in mice with isoproterenol (ISP) -induced heart failure were investigated."	8.31	Intravenous Semaphorin 3A Administration Maintains Cardiac Contractility and Improves Electrical Remodeling in a Mouse Model of Isoproterenol-Induced Heart Failure. ( Hagikura, K; Hao, H; Kashimoto, M; Kurokawa, S; Matsumoto, T; Nagashima, K; Okumura, Y; Otsuka, N; Shimodai-Yamada, S; Wakamatsu, Y, 2023)
"Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy."	8.31	Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023)
"Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure."	8.31	Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023)
"To evaluate the cardioprotective effects and the potential mechanisms of the ethanol extracts of SD-3 against isoproterenol (ISO)-induced heart failure (HF) in rats."	8.12	Cardioprotective effect of ethanol extracts of Sugemule-3 decoction on isoproterenol-induced heart failure in Wistar rats through regulation of mitochondrial dynamics. ( Bai, X; Fu, DN; Liu, MJ; Na, RS; Wang, Y; Wei, CX; Yu, LJ; Zhen, D, 2022)
"This study is aimed at determining the expression and function of the GASL1 and PI3K/AKT pathways in isoproterenol- (ISO-) induced heart failure (HF)."	8.12	Valsartan Regulates PI3K/AKT Pathways through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure. ( Duan, X; Feng, Y; Wang, J; Yuan, J; Zhou, J, 2022)
"To evaluate the effects of Huoxin Pill (, HXP) on cardiac fibrosis and heart failure (HF) in isoproterenol (ISO)-induced HF rats."	8.02	Huoxin Pill () Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats. ( Chu, JF; Huang, B; Li, Q; Lu, Y; Peng, J; Peng, MZ; Shen, AL; Shen, ZQ; Yang, ML; Zhou, XL, 2021)
"This study was designed to delineate the effect of kaempferol (KF) on heart failure (HF) in diabetic rats."	7.91	The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats. ( Geng, J; Guo, Z; Han, S; Wang, Y; Zhang, L, 2019)
"The present study aimed to investigate the potential effects of growth differentiation factor 11 (GDF11) on isoproterenol (ISO)‑induced heart failure (HF) and identify the underlying molecular mechanisms."	7.91	Growth differentiation factor 11 is involved in isoproterenol‑induced heart failure. ( Hao, Z; Jia, Y; Li, N; Shi, ZF; Tan, H; Zhang, XJ, 2019)
"The purpose of the present study was to evaluate the cardioprotective effect of ulinastatin against isoproterenol‑induced chronic heart failure (CHF)."	7.88	Cardioprotective effects of ulinastatin against isoproterenol-induced chronic heart failure through the PI3K‑Akt, p38 MAPK and NF-κB pathways. ( Hao, J; Jiang, X; Li, L; Li, P; Sen, H, 2018)
"Isoproterenol is used widely for inducing heart failure in mice."	7.88	Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation. ( Chang, SC; Rau, CD; Ren, S; Wang, JJ, 2018)
"To evaluate the effect of oltipraz (OPZ) on isoproterenol-induced heart failure (HF) and heart function."	7.88	Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. ( Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY, 2018)
"There may be cardio-renal interactions in rats of isoproterenol-induced heart failure, which may be associated with renal fibrosis and endothelial-to-mesenchymal transition (EndMT)."	7.85	Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure. ( Cai, J; Chen, L; Chen, X; Ge, W; Zheng, G; Zhou, H; Zhou, X, 2017)
"We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy."	7.85	Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017)
"Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure model by subcutaneous injection."	7.85	Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway. ( Ma, P; Wang, Y; Xiong, A; Xu, Q; Xu, Y; Zhou, R, 2017)
"1-KATP channel opener, against chronic heart failure induced by isoproterenol in rats were investigated."	7.83	Natakalim Ameliorates Isoproterenol-Induced Chronic Heart Failure by Protecting against Endothelial Dysfunction. ( Cui, W; Long, C; Wang, H; Zhang, H; Zhang, Y; Zhong, M; Zhou, H, 2016)
"We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced heart failure model in mice, which allowed control of confounding factors in an experimental setting."	7.83	Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. ( Avetisyan, R; Gong, KW; Lusis, AJ; Rau, C; Ren, S; Romay, MC; Stolin, G; Wang, JJ; Wang, Y, 2016)
"A total of 30 male Wistar albino rats at 12 weeks of age were randomly divided into three groups: control, isoproterenol-induced heart failure group (ISO), and isoproterenol-induced heart failure + V."	7.83	Cardioprotective effects of Viscum album L. ssp. album (Loranthaceae) on isoproterenol-induced heart failure via regulation of the nitric oxide pathway in rats. ( Karagöz, A; Kesici, S; Semerci, T; Teker, E; Tezcan, B; Usta, M; Vural, A, 2016)
"The aim of the present study was to confirm the effect of Tanshinone IIA (TAN) on the prevention of AF in chronic heart failure (CHF), and to elucidate the underlying electrophysiological mechanisms for the antiarrhythmic effects of TAN at the level of the atrium in an experimental model of CHF."	7.83	Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure. ( Cheng, D; He, Z; Sun, C; Xu, Y, 2016)
" The aim of the present study was to investigate whether nicorandil could offer an additional benefit over bone marrow-derived mesenchymal stem cell therapy in isoproterenol-induced myocardial damage and its progression to heart failure in rats."	7.81	Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats. ( Ahmed, LA; Attia, WA; Khattab, MM; Mohamed, SS, 2015)
"RDN can effectively attenuate the left atrial fibrosis in rats with isoproterenol induced chronic heart failure."	7.81	[Effects of renal denervation on left atrial fibrosis in rats with isoproterenol induced chronic heart failure]. ( Li, Z; Liu, Q; Lu, D; Shan, Q; Wang, K; Wang, S; Zhang, Q, 2015)
"Myocardial infarction (MI) was induced by subcutaneous injection of isoproterenol (ISO) to investigate the effect of ISO on Coenzyme Q10 (CoQ10) content of myocardium and subsequent effects on lipid peroxidation, electrocardiogram pattern and hemodynamic parameters of the rat's heart."	7.80	Reduction of coenzyme q10 content: a possible effect of isoproterenol on heart failure and myocardial infarction in rat. ( Andalib, S; Garjani, A; Ghanbarzadeh, S; Khorrami, A, 2014)
" A subcutaneous injection of isoproterenol (5 mg/kg/day) for 10 days was used for the induction of heart failure."	7.80	Atorvastatin reduces the myocardial content of coenzyme Q10 in isoproterenol-induced heart failure in rats. ( Andalib, S; Garjani, A; Khorrami, A; Maleki-Dijazi, N; Shayanfar, A, 2014)
" This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure."	7.80	Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014)
"To investigate the protective effects of oxymatrine on chronic heart failure induced by isoproterenol (ISO) and to observe its effects on ADMA metabolism pathway in ISO-induced chronic heart failure in rats."	7.80	[Protective effect of oxymatrine on chronic heart failure and ADMA metabolism pathway in isoproterenol-induced chronic heart failure in rats]. ( Dai, GD; Ma, P; Wang, Y; Xiong, AQ; Xu, QB; Xu, YH; Yuan, YN; Zheng, P, 2014)
"The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood."	7.80	Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014)
"This study aimed to investigate the effects of thoracic epidural anesthesia (TEA) on cardiac function and myocardial cell apoptosis in isoproterenol (ISO) induced chronic heart failure (CHF) rats."	7.80	Effects of thoracic epidural anesthesia on cardiac function and myocardial cell apoptosis in isoproterenol-induced chronic heart failure rats. ( Chang, HY; Ge, T; Guo, L; Han, W; Qin, H; Wang, X; Yang, SS, 2014)
"The present study was designed to investigate whether oxymatrine could attenuate isoproterenol-induced heart failure via regulation of asymmetric dimethylarginine (ADMA) metabolism in rats."	7.80	Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. ( Dai, G; Liu, J; Liu, YK; Wang, X; Wang, Y; Xu, Q; Xu, X; Zhang, J; Zhang, W, 2014)
"Castration significantly increased cardiomyocyte apoptosis and fibrosis that was normally induced by isoproterenol (P<0."	7.78	Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. ( Cao, JX; Fu, L; Han, Y; Kang, NN; Sun, JF; Xu, J; Zheng, M, 2012)
"Ranolazine (RAN) was reported to be effective and safe in converting atrial fibrillation (AF) to sinus rhythm by administration of a single dose ('pill in the pocket') to patients with structural heart disease."	7.78	Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. ( Clauß, C; Eckardt, L; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Schmidt, M; Stypmann, J, 2012)
"The present study demonstrated prophylactic and therapeutic potential of Terminalia arjuna bark extract in isoproterenol (ISO)-induced chronic heart failure (CHF)."	7.77	Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. ( Agarwal, S; Babbar, R; Fahim, M; Kotwani, A; Parveen, A, 2011)
"Heart failure was induced by isoproterenol in male Sprague-Dawley rats."	7.77	Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. ( Cai, H; Cao, SP; Gu, N; Qian, CF; Song, YH; Zhao, ZM, 2011)
"The effect of atorvastatin on cardiac remodeling, function, and homodynamic parameters in isoproterenol-induced heart failure was evaluated in the present study."	7.77	Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. ( Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H, 2011)
" The heart failure model was induced by injection of isoproterenol (ISO) 340 mg/kg continuously two days."	7.77	Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats. ( Li, Y; Qu, XF; Song, Y; Sun, SQ; Wang, SJ; Wang, XT; Yu, Y, 2011)
"Our study demonstrates the contribution of IL-17 to myocardial fibrosis in isoproterenol-induced HF."	7.75	IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. ( Feng, W; Li, W; Li, Y; Liu, W; Wang, F; Yan, W, 2009)
"Isoproterenol-induced cardiac hypertrophy in mice has been used in a number of studies to model human cardiac disease."	7.75	Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. ( Errami, M; Galindo, CL; Garner, HR; Kumar, NM; Li, J; McCormick, JF; McIver, LJ; Olson, LD; Pham, TQ; Skinner, MA; Watson, DA, 2009)
"A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure."	7.74	Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008)
"To study the treatment effect of Wenxin Keli on isoproterenol (ISO) induced heart failure in rats."	7.74	[Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats]. ( Hu, SJ; Mu, Y; Zhou, F, 2007)
"Heart failure (HF) may be produced by sustained beta-adrenoceptor stimulation by causing changes in the expression of endothelin-1 (ET-1), the leptin system, calcineurin and sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) underlying cardiac dysfunction."	7.74	Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats. ( Dai, DZ; Dai, Y; Ji, H; Tang, XY; Xu, M, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."	7.73	Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol."	7.73	Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005)
"Hyperphosphorylation of the cardiac Ca2+ release channel (ryanodine receptor, RyR2) by protein kinase A (PKA) at serine-2808 has been proposed to be a key mechanism responsible for cardiac dysfunction in heart failure (HF)."	7.73	Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. ( Chen, SR; Cheng, H; Jiang, MT; Lai, FA; Sutherland, C; Walsh, MP; Warltier, DC; Xiao, B; Yang, D; Zhao, M, 2005)
"The role of phosphorylation of the ryanodine receptor at serine-2808 (RyRS2808) in congestive heart failure (CHF) is controversial, and effects of RyRS2808 phosphorylation on contraction are unclear."	7.73	Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. ( Chen, SR; Davidoff, AW; Mei, J; Obayashi, M; Stuyvers, BD; ter Keurs, HE; Xiao, B, 2006)
"The purpose of present study was to investigate the effect of metabolic substrate pyruvate and beta-adrenergic agonist isoproterenol and combination of these agents on the force- and relaxation-frequency relationship in human heart failure."	7.73	The force-frequency relationship in human heart failure: effect of pyruvate and isoproterenol. ( Gendviliene, V; Gurskaite, H; Martisiene, I; Zablockaite, D, 2005)
"Animals with heart failure exhibited depressions in ventricular function, positive inotropic response to isoproterenol, beta-AR receptor density and basal AC activity; these changes were also attenuated by PLC treatment."	7.72	Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. ( Dhalla, NS; Ferrari, R; Sethi, R; Wang, X, 2004)
"These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure."	7.72	Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004)
"Furosemide shortened the time to left ventricular dysfunction (35."	7.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
"We measured cardiac conformation, contractile performance and cytokines level in 8 age-matched normal adult rats (control group) and 8 rats with isoproterenol (ISO)-induced Heart failure (ISO group) and 8 rats with ISO-induced lesion but received EB treatment (EB group)."	7.71	Chronic treatment of enbrel in rats with isoproterenol-induced congestive heart failure limits left ventricular dysfunction and remodeling. ( Gan, R; Li, W; Sun, G, 2002)
"In rats, a toxic dosage of isoproterenol caused characteristic myocardial damage that subsequently resulted in mild heart failure."	7.70	Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. ( Bruckschlegel, G; Elsner, D; Griese, D; Grimm, D; Kromer, EP; Muders, F; Pfeifer, M; Riegger, GA; Schunkert, H, 1998)
"Long-term metoprolol therapy improves cardiac performance and decreases mortality in patients with chronic congestive heart failure (CHF)."	7.70	Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. ( DiBona, GF; Sawin, LL, 1999)
"We conclude that endogenous catecholamines, acting via beta 2-adrenergic receptors, attenuate the permeability response to histamine in pacing-induced heart failure."	7.70	Attenuation of histamine-induced endothelial permeability responses after pacing-induced heart failure: role for endogenous catecholamines. ( Dougherty, FC; Dyess, DL; Hunter, JL; Lakey, JR; Moyer, D; Townsley, MI, 2000)
" To examine the status of beta-adrenergic receptors and postadrenergic receptor mechanisms in congestive heart failure due to myocardial infarction, the left coronary artery in rats was ligated for 4 and 8 weeks before studying the hemodynamic and biochemical changes due to isoproterenol, a beta-adrenoceptor agonist, or forskolin, a postreceptor agonist."	7.69	Inotropic responses to isoproterenol in congestive heart failure subsequent to myocardial infarction in rats. ( Dhalla, NS; Sethi, R, 1995)
"The aim was to investigate the pattern of release of atrial natriuretic factor induced by mechanical and adrenergic stimulation from atria of rats with or without congestive heart failure."	7.68	Effect of congestive heart failure on rate of atrial natriuretic factor release in response to stretch and isoprenaline. ( Agnoletti, G; Cornacchiari, A; De Giuli, F; Ferrari, R; Ghielmi, S; Panzali, AF, 1990)
"Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were investigated."	7.67	[Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs]. ( Sonoki, H; Sugimoto, T; Tomaru, T; Uchida, Y, 1988)
"Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption."	7.67	Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985)
"Thirty-one age-matched, conscious, virgin, male Sprague-Dawley rats and spontaneously hypertensive rats (SHRs) were individually injected with a single subcutaneous dose of 85 mg/kg dl-isoproterenol to determine the degree and time course of drug-induced cardiac failure and functional recovery."	7.66	Isoproterenol-induced cardiac failure in the spontaneously hypertensive rat. ( Iams, SG; Yeager, JC, 1981)
"Hemodynamic responses to propranolol and isoproterenol were examined in elderly patients with heart failure."	7.66	Studies on heart failure in old age (Part II). Hemodynamic effects of propranolol and isoproterenol in elderly patients with heart failure. ( Mifune, J, 1978)
"The inotropic response of the left ventricle to intravenous administration of norepinephrine (NE) and isoproterenol (I) was studied in dogs with congestive heart failure (CHF) resulting from aortocaval fistula."	7.65	A depressed response of left ventricular contractile force to isoproterenol and norepinephrine in dogs with congestive heart failure. ( Newman, WH, 1977)
"Cardiac fibrosis is an essential structural remodeling associated with HF; therefore, preventing cardiac fibrosis is crucial to decelerating the progression of HF."	5.91	Sodium houttuyfonate against cardiac fibrosis attenuates isoproterenol-induced heart failure by binding to MMP2 and p38. ( Adu-Amankwaah, J; An, K; Cui, J; Lin, L; Song, N; Sun, H; Tan, R; Wang, M; You, Q; Yuan, J, 2023)
"Cardiac hypertrophy was induced in rats by subcutaneous injection of isoproterenol (ISO, 1."	5.91	JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit. ( Cai, SD; Feng, GS; Guo, Z; Hu, YH; Javaheri, A; Li, Q; Li, ZZ; Liang, LY; Liu, PQ; Lu, J; Luo, WW; Valenzuela Ripoll, C; Wang, L; Wang, QQ; Wu, ZK; Zhang, JG, 2023)
"Ferulic acid (FA) has potential therapeutic effects in multiple diseases including cardiovascular diseases."	5.62	Ferulic Acid Ameliorates Isoproterenol-Induced Heart Failure by Decreasing Oxidative Stress and Inhibiting Cardiocyte Apoptosis via Activating Nrf2 Signaling Pathway in Rats. ( Cui, ZH; He, TT; Liang, XW; Wang, L; Zhang, XJ; Zhao, YX, 2021)
"Recent data show that cardiac hypertrophy contributes substantially to the overall heart failure burden."	5.56	STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. ( Ke, Q; Liu, B; Liu, F; Mei, Y; Su, H; Sun, X; Tan, W, 2020)
"Mangiferin is a well-known xanthone extracted from mango leaves (Mangifera indica Linn)."	5.56	Mangiferin exert cardioprotective and anti-apoptotic effects in heart failure induced rats. ( Gao, G; Han, F; Jiang, T; Liu, M, 2020)
"Isoproterenol (ISO), is a non-selective beta-adrenergic agonist, that is used widely to induce cardiac injury in mice."	5.51	Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice. ( Chang, S; Mandelli, A; Ren, S; Tran, A; Wang, JJ; Wang, Y, 2019)
" A histological analysis revealed that chronic intake of MEL diminished the age-dependent changes in the structure of muscle fibers of the left ventricle, muscle fiber swelling, and injury zones characteristic of acute cardiac failure caused by ISO."	5.48	Effect of Melatonin on Rat Heart Mitochondria in Acute Heart Failure in Aged Rats. ( Akatov, V; Baburina, Y; Fadeeva, I; Krestinina, O; Kruglov, A; Odinokova, I; Sotnikova, L; Zvyagina, A, 2018)
"Fusaric acid (FA) is a novel compound derived from a class of nicotinic acid derivatives, exhibiting activity against cancers."	5.46	Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways. ( Li, X; Wang, HF; Zhang, ZL, 2017)
"Isoproterenol (ISO) has been widely used to establish cardiac injury in vivo and in vitro."	5.46	Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress. ( Chen, DL; Wang, Z; Yang, J, 2017)
"Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes."	5.42	Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015)
"The extent of heart failure has been estimated by supersonic inspection 28 and 60 days after isoproterenol injections."	5.35	[The density of myocardial and pericardial rat mast cells in isoproterenol-induced heart failure]. ( Emel'ianova, OI; Erokhina, IL; Kazachenko, AA; Kulikov, AN; Martynova, MG; Moiseeva, OM; Okovityĭ, SV; shulenin, SN, 2008)
"Global heart failure was induced in Wistar rats by isoproterenol injection."	5.35	Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. ( Guan, Z; Li, L; Li, Y; Xu, Y; Yu, B; Zhang, Y; Zhao, S, 2008)
"Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist."	5.33	Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005)
"Selegiline is a centrally acting sympatholytic agent with neuroprotective properties."	5.31	Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure. ( Dong, E; Kawai, H; Liang, CS; Shite, J; Stevens, SY, 2000)
"Propofol has a direct and negative effect on basal myocyte contractile processes in the setting of CHF, which is more pronounced than that on healthy myocytes at reduced propofol concentrations."	5.30	Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing-induced congestive heart failure. ( Clair, MJ; Dorman, BH; Hebbar, L; Roy, RC; Spinale, FG, 1997)
"If operative in patients with congestive heart failure (CHF), such receptors could participate in positive feedback cycles amplifying sympathoactivation."	5.30	Regulation of regional norepinephrine spillover in heart failure: the effect of angiotensin II and beta-adrenergic agonists in the forearm circulation. ( Garr, M; Goldsmith, SR; McLaurin, M, 1998)
"The propranolol treated animals had higher LV end-diastolic pressures (27+/-2* vs 20+/(-3 mmHg) and a more restricted LV diastolic filling pattern (increased ratio of early to late filling velocities and more rapid E wave deceleration rate)."	5.30	Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. ( Douglas, PS; Katz, SE; Litwin, SE; Morgan, JP, 1999)
"Mibefradil treatment increased MAP and dP/dtmax and decreased LVEDP and HR in infarcted rats."	5.30	Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats. ( Meissner, A; Min, JY; Sandmann, S; Unger, T, 1999)
"Captopril treatment led to an up-regulation of cardiac beta 1- but not mononuclear leukocyte beta 2-adrenergic receptors and an increase in isoproterenol-stimulated adenylate cyclase activity in the heart."	5.28	Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. ( Carter, SM; Maisel, AS; Michel, MC; Phillips, C; Ziegler, MG, 1989)
"Adenosine is a metabolic coronary vasodilator [1] and also has recently been shown to antagonize the inotropic action of beta-adrenergic agonists through a mechanism involving action on the sarcolemmal adenylate cyclase system [4, 13]."	5.27	Increased myocardial adenosine release in heart failure. ( Frankis, MB; Grossman, SJ; Newman, WH; Webb, JG, 1984)
"The extent of cardiac failure was isoproterenol dose dependent."	5.26	The hemodynamics of isoproterenol-induced cardiac failure in the rat. ( Iams, SG; Yeager, JC, 1981)
" Additionally, dose-response curves of CF in response to injected norepinephrine, isoproterenol, glucagon, and calcium were depressed when compared to the normal group while the response of heart rate and blood pressure was not different."	5.26	Volume overload heart failure: length-tension curves, and response to beta-agonists, Ca2+, and glucagon. ( Newman, WH, 1978)
" Patients suffering from congestive heart failure were treated with Digitalis, other patients with normal hearts were subjected to infusion therapy of Isoproterenol, Propranolol, Verapamil and Calcium chloride."	5.04	[Echocardiographic evaluation of left ventricular function during therapy with cardiovascularly effective drugs]. ( Stefan, G, 1976)
" In this paper the oxygen consumption and oxygen transport, heart failure in the newborn, effects of non glycoside inotropic agents in general and the doses of the commonly used inotropic agents (dopamine, dobutamine and isoproterenol) will be discussed."	4.78	[Application of non-glycoside inotropic agents in newborn infants]. ( Szatmari, A; Terlouw, JF; Umans-Eckenhausen, MA; van den Anker, JN, 1993)
"Myocardial infarction was induced by injecting subcutaneous isoproterenol (5 mg/kg once for 7 consecutive days) to establish an experimental heart failure model."	4.31	Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach. ( Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F, 2023)
" However, the effect and potential mechanism of OMT on isoproterenol (ISO)-induced heart failure (HF) are not clear."	4.31	Oxymatrine attenuated isoproterenol-induced heart failure via the TLR4/NF-κB and MAPK pathways in vivo and in vitro. ( Bai, J; Fu, D; Sun, H; Sun, Y; Wang, Y; Wei, C; Zhen, D, 2023)
" Hemodynamics, lipid profile, liver enzymes, urea, and creatinine were assessed in conjunction with heart failure markers (serum NT-proANP and cTnI)."	4.31	Inhibition of transglutaminase 2 (TG2) ameliorates ventricular fibrosis in isoproterenol-induced heart failure in rats. ( Abusara, S; Al-Dwairi, A; Al-Shboul, O; Al-U'datt, DGF; AlQudah, M; Altuntas, Y; Alu'datt, M; Alzoubi, KH; Hiram, R; Jaradat, S; Tranchant, CC, 2023)
"The effects of recombinant semaphorin 3A (Sema3A) on myocardial contractility and electrical remodeling in mice with isoproterenol (ISP) -induced heart failure were investigated."	4.31	Intravenous Semaphorin 3A Administration Maintains Cardiac Contractility and Improves Electrical Remodeling in a Mouse Model of Isoproterenol-Induced Heart Failure. ( Hagikura, K; Hao, H; Kashimoto, M; Kurokawa, S; Matsumoto, T; Nagashima, K; Okumura, Y; Otsuka, N; Shimodai-Yamada, S; Wakamatsu, Y, 2023)
"Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy."	4.31	Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023)
"Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure."	4.31	Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023)
"To evaluate the cardioprotective effects and the potential mechanisms of the ethanol extracts of SD-3 against isoproterenol (ISO)-induced heart failure (HF) in rats."	4.12	Cardioprotective effect of ethanol extracts of Sugemule-3 decoction on isoproterenol-induced heart failure in Wistar rats through regulation of mitochondrial dynamics. ( Bai, X; Fu, DN; Liu, MJ; Na, RS; Wang, Y; Wei, CX; Yu, LJ; Zhen, D, 2022)
"This study is aimed at determining the expression and function of the GASL1 and PI3K/AKT pathways in isoproterenol- (ISO-) induced heart failure (HF)."	4.12	Valsartan Regulates PI3K/AKT Pathways through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure. ( Duan, X; Feng, Y; Wang, J; Yuan, J; Zhou, J, 2022)
"To explore the molecular mechanism by which Shengmaiyin (Codonopsis pilosula) (SMY) improves isoproterenol (ISO)-induced heart failure (HF) in rats via a traditional Chinese medicine (TCM) integrated pharmacology research platform, The Chinese Medicine Integrated Pharmacology Platform (TCMIP V2."	4.12	Investigating the Mechanism of Shengmaiyin ( ( Kan, M; Li, N; Li, Z; Lin, J; Lin, Z; Liu, X; Liu, Y; Ming, S; Pang, Q; Sui, X; Wang, J; Yang, Q; Zhang, Y; Zhang, Z, 2022)
"This study investigated the protective effects of Compound 21 (C21), the first specific non-peptide AT2 receptor agonist, on cardiac injury in rats with isoproterenol-induced heart failure in vivo and compared it with valsartan, an AT1 receptor antagonist."	4.02	The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats. ( Ates, B; Colak, C; Ermis, N; Ozhan, O; Parlakpinar, H; Ulutas, Z; Vardi, N, 2021)
"To evaluate the effects of Huoxin Pill (, HXP) on cardiac fibrosis and heart failure (HF) in isoproterenol (ISO)-induced HF rats."	4.02	Huoxin Pill () Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats. ( Chu, JF; Huang, B; Li, Q; Lu, Y; Peng, J; Peng, MZ; Shen, AL; Shen, ZQ; Yang, ML; Zhou, XL, 2021)
" We determined that the knockout of WWP2 specifically in myocardium decreased the level of PARP1 ubiquitination and increased the effects of isoproterenol (ISO)-induced PARP1 and PARylation, in turn aggravating ISO-induced myocardial hypertrophy, heart failure, and myocardial fibrosis."	3.96	Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling. ( Cao, L; Qian, H; Sun, Y; Wu, S; Zhang, N; Zhang, Y, 2020)
"Isoproterenol (ISO)-induced heart failure is a standardized model for the study of beneficial effects of various drugs."	3.96	Angiotensin (1-7) and Apelin co-therapy: New strategy for heart failure treatment of rats. ( Gholampour, Y; Javanmardi, K; Soltani Hekmat, A; Tavassoli, A, 2020)
"This study was designed to delineate the effect of kaempferol (KF) on heart failure (HF) in diabetic rats."	3.91	The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats. ( Geng, J; Guo, Z; Han, S; Wang, Y; Zhang, L, 2019)
"The present study aimed to investigate the potential effects of growth differentiation factor 11 (GDF11) on isoproterenol (ISO)‑induced heart failure (HF) and identify the underlying molecular mechanisms."	3.91	Growth differentiation factor 11 is involved in isoproterenol‑induced heart failure. ( Hao, Z; Jia, Y; Li, N; Shi, ZF; Tan, H; Zhang, XJ, 2019)
" Hence, the aim of this study was to describe alterations in and show potential correlations between the structural characteristics and the molecular and biochemical markers of cardiac remodelling on a model of isoproterenol-induced heart failure."	3.91	Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model. ( Adamcova, M; Aziriova, S; Baka, T; Dolezelova, E; Karesova, I; Krajcirovicova, K; Repova, K; Simko, F; Stanko, P, 2019)
"The purpose of the present study was to evaluate the cardioprotective effect of ulinastatin against isoproterenol‑induced chronic heart failure (CHF)."	3.88	Cardioprotective effects of ulinastatin against isoproterenol-induced chronic heart failure through the PI3K‑Akt, p38 MAPK and NF-κB pathways. ( Hao, J; Jiang, X; Li, L; Li, P; Sen, H, 2018)
"Isoproterenol is used widely for inducing heart failure in mice."	3.88	Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation. ( Chang, SC; Rau, CD; Ren, S; Wang, JJ, 2018)
"To evaluate the effect of oltipraz (OPZ) on isoproterenol-induced heart failure (HF) and heart function."	3.88	Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. ( Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY, 2018)
"There may be cardio-renal interactions in rats of isoproterenol-induced heart failure, which may be associated with renal fibrosis and endothelial-to-mesenchymal transition (EndMT)."	3.85	Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure. ( Cai, J; Chen, L; Chen, X; Ge, W; Zheng, G; Zhou, H; Zhou, X, 2017)
"We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy."	3.85	Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017)
"Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure model by subcutaneous injection."	3.85	Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway. ( Ma, P; Wang, Y; Xiong, A; Xu, Q; Xu, Y; Zhou, R, 2017)
" The β-AR agonist isoproterenol (Iso) induced heart failure with high mortality in postpartum female, in non-pregnant female and in male CKO, but not in wild-type mice."	3.85	Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. ( Bauersachs, J; Bengel, FM; Bogeski, I; Erschow, S; Haghikia, A; Hagl, C; Hilfiker-Kleiner, D; Jauhiainen, M; Kappl, R; Knuuti, J; Kohlhaas, M; Maack, C; Müller, M; Nickel, AG; Pietzsch, S; Ricke-Hoch, M; Roivainen, A; Saar, JA; Saraste, A; Scherr, M; Sieve, I; Silvola, JM; Stapel, B; Thackeray, JT; Tudorache, I, 2017)
"We conducted genome-wide measurements of DNA methylation in different strains of mice that are susceptible and resistant to isoproterenol-induced dysfunction to test the hypothesis that this epigenetic mark may play a causal role in the development of heart failure."	3.83	DNA Methylation Indicates Susceptibility to Isoproterenol-Induced Cardiac Pathology and Is Associated With Chromatin States. ( Chen, H; Lusis, AJ; Orozco, LD; Pellegrini, M; Rau, CD; Ren, S; Rubbi, L; Vondriska, TM; Wang, J; Wang, Y, 2016)
"1-KATP channel opener, against chronic heart failure induced by isoproterenol in rats were investigated."	3.83	Natakalim Ameliorates Isoproterenol-Induced Chronic Heart Failure by Protecting against Endothelial Dysfunction. ( Cui, W; Long, C; Wang, H; Zhang, H; Zhang, Y; Zhong, M; Zhou, H, 2016)
"We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced heart failure model in mice, which allowed control of confounding factors in an experimental setting."	3.83	Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. ( Avetisyan, R; Gong, KW; Lusis, AJ; Rau, C; Ren, S; Romay, MC; Stolin, G; Wang, JJ; Wang, Y, 2016)
"A total of 30 male Wistar albino rats at 12 weeks of age were randomly divided into three groups: control, isoproterenol-induced heart failure group (ISO), and isoproterenol-induced heart failure + V."	3.83	Cardioprotective effects of Viscum album L. ssp. album (Loranthaceae) on isoproterenol-induced heart failure via regulation of the nitric oxide pathway in rats. ( Karagöz, A; Kesici, S; Semerci, T; Teker, E; Tezcan, B; Usta, M; Vural, A, 2016)
"The aim of the present study was to confirm the effect of Tanshinone IIA (TAN) on the prevention of AF in chronic heart failure (CHF), and to elucidate the underlying electrophysiological mechanisms for the antiarrhythmic effects of TAN at the level of the atrium in an experimental model of CHF."	3.83	Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure. ( Cheng, D; He, Z; Sun, C; Xu, Y, 2016)
" Cardiomyopathy results from cardiac injury, is the leading cause of heart failure, and can be induced in heart failure-prone rats through sub-chronic infusion of isoproterenol (ISO)."	3.81	Cardiomyopathy confers susceptibility to particulate matter-induced oxidative stress, vagal dominance, arrhythmia and pulmonary inflammation in heart failure-prone rats. ( Carll, AP; Cascio, WE; Costa, DL; Farraj, AK; Haykal-Coates, N; Hazari, MS; Ledbetter, AD; Richards, JH; Winsett, DW, 2015)
"Recent evidence has shown that, in heart failure (HF), clinically relevant concentrations of angiotensin-(1-7) [Ang-(1-7)] counteracts angiotensin II induced cardiac depression and produces positive inotropic effects in both left ventricle (LV) and myocytes."	3.81	Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failure. ( Cheng, CP; Cheng, HJ; Ferrario, CM; Li, T; Zhou, P, 2015)
"To assess the impact of transfection with recombinant adenovirus vector-mediated Klotho gene on myocardial remodeling in a rat model of heart failure (HF) by intraperitoneal injection of isoproterenol."	3.81	[Impact of transfection with recombinant adenovirus vector-mediated Klotho gene on myocardial remodeling in a rat model of heart failure]. ( Chen, W; Gan, S; Jia, Z; Liu, Q; Wei, L; Yang, J; Yang, X; Zhang, L; Zhu, Z, 2015)
" The aim of the present study was to investigate whether nicorandil could offer an additional benefit over bone marrow-derived mesenchymal stem cell therapy in isoproterenol-induced myocardial damage and its progression to heart failure in rats."	3.81	Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats. ( Ahmed, LA; Attia, WA; Khattab, MM; Mohamed, SS, 2015)
"RDN can effectively attenuate the left atrial fibrosis in rats with isoproterenol induced chronic heart failure."	3.81	[Effects of renal denervation on left atrial fibrosis in rats with isoproterenol induced chronic heart failure]. ( Li, Z; Liu, Q; Lu, D; Shan, Q; Wang, K; Wang, S; Zhang, Q, 2015)
"Myocardial infarction (MI) was induced by subcutaneous injection of isoproterenol (ISO) to investigate the effect of ISO on Coenzyme Q10 (CoQ10) content of myocardium and subsequent effects on lipid peroxidation, electrocardiogram pattern and hemodynamic parameters of the rat's heart."	3.80	Reduction of coenzyme q10 content: a possible effect of isoproterenol on heart failure and myocardial infarction in rat. ( Andalib, S; Garjani, A; Ghanbarzadeh, S; Khorrami, A, 2014)
" Chronic injection with the β-adrenoceptor (β-AR) agonist isoproterenol (ISO) has been commonly used as an animal model of β-AR-induced cardiac remodelling and heart failure."	3.80	Echocardiographic assessment of β-adrenoceptor stimulation-induced heart failure with reduced heart rate in mice. ( Chen, C; Li, H; Lu, ZZ; Song, Y; Xiao, H; Zhang, YY, 2014)
" A subcutaneous injection of isoproterenol (5 mg/kg/day) for 10 days was used for the induction of heart failure."	3.80	Atorvastatin reduces the myocardial content of coenzyme Q10 in isoproterenol-induced heart failure in rats. ( Andalib, S; Garjani, A; Khorrami, A; Maleki-Dijazi, N; Shayanfar, A, 2014)
"Consecutive treatment of normal heart with a high dose of isoproterenol and adenosine (Iso/Ade treatment), confers strong protection against ischaemia/reperfusion injury."	3.80	Clinically-relevant consecutive treatment with isoproterenol and adenosine protects the failing heart against ischaemia and reperfusion. ( Bryant, SM; Dudley, DJ; Halestrap, AP; James, AF; Khaliulin, I; Suleiman, MS, 2014)
" This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure."	3.80	Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014)
"To investigate the protective effects of oxymatrine on chronic heart failure induced by isoproterenol (ISO) and to observe its effects on ADMA metabolism pathway in ISO-induced chronic heart failure in rats."	3.80	[Protective effect of oxymatrine on chronic heart failure and ADMA metabolism pathway in isoproterenol-induced chronic heart failure in rats]. ( Dai, GD; Ma, P; Wang, Y; Xiong, AQ; Xu, QB; Xu, YH; Yuan, YN; Zheng, P, 2014)
" Most importantly, we found that epicardial application of resiniferatoxin largely prevented the elevated left ventricle end-diastolic pressure, lung edema, and cardiac hypertrophy, partially reduced left ventricular dimensions in the failing heart, and increased cardiac contractile reserve in response to β-adrenergic receptor stimulation with isoproterenol in CHF rats."	3.80	Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. ( Cornish, KG; Rozanski, GJ; Wang, HJ; Wang, W; Zucker, IH, 2014)
"The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood."	3.80	Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014)
"Introduction of isoproterenol (an agonist of beta-adrenoreceptors) to rats is one of the widespread experimental models of cardiac failure."	3.80	[Complex study of the rat heart at isoproterenol damage]. ( Abramov, VS; Ermishkin, VV; Gramovich, VV; Kapel'ko, VI; Lakomkin, SV; Lakomkin, VL; Lukoshkova, EV; Shirinskiĭ, VP; Undrovinas, NA; Veselova, SP; Vyborov, ON; Zhdanov, VS, 2014)
"Enhanced arginine vasopressin levels are associated with increased mortality during end-stage human heart failure, and cardiac arginine vasopressin type 1A receptor (V1AR) expression becomes increased."	3.80	β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. ( Barr, LA; Carter, RL; Cheung, JY; Coleman, RC; Feldman, AM; Gao, E; Grisanti, LA; Houser, SR; Koch, WJ; Li, X; Makarewich, CA; Myers, VD; Song, J; Tilley, DG; Troupes, CD; Yu, D; Zhu, W, 2014)
"This study aimed to investigate the effects of thoracic epidural anesthesia (TEA) on cardiac function and myocardial cell apoptosis in isoproterenol (ISO) induced chronic heart failure (CHF) rats."	3.80	Effects of thoracic epidural anesthesia on cardiac function and myocardial cell apoptosis in isoproterenol-induced chronic heart failure rats. ( Chang, HY; Ge, T; Guo, L; Han, W; Qin, H; Wang, X; Yang, SS, 2014)
"The present study was designed to investigate whether oxymatrine could attenuate isoproterenol-induced heart failure via regulation of asymmetric dimethylarginine (ADMA) metabolism in rats."	3.80	Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. ( Dai, G; Liu, J; Liu, YK; Wang, X; Wang, Y; Xu, Q; Xu, X; Zhang, J; Zhang, W, 2014)
"In Wistar rats, cardiac hypertrophy and heart failure were induced by subcutaneous injection of isoproterenol (Iso)."	3.79	Role of the calcium-sensing receptor in cardiomyocyte apoptosis via the sarcoplasmic reticulum and mitochondrial death pathway in cardiac hypertrophy and heart failure. ( Dong, S; Fu, SB; Leng, X; Li, H; Lu, FH; Ren, H; Xu, CQ; Zhang, WH; Zhang, X; Zhao, YJ; Zhong, X, 2013)
"In PKA inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibrosis, and myocyte apoptosis, and decreased cardiac function."	3.79	Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. ( Ai, X; Chen, X; Fu, Q; Gao, E; Gao, H; Ge, XJ; Jin, J; Kunapuli, SP; Li, Y; Makarewich, C; Szeto, C; Tang, A; Tang, M; Wang, F; Wang, J; Xiang, KY; Zeng, C; Zhang, X; Zhou, L, 2013)
"Castration significantly increased cardiomyocyte apoptosis and fibrosis that was normally induced by isoproterenol (P<0."	3.78	Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. ( Cao, JX; Fu, L; Han, Y; Kang, NN; Sun, JF; Xu, J; Zheng, M, 2012)
" Heart failure (HF) was induced by isoproterenol (ISO)."	3.78	Evaluation of antioxidant and immunity function of tetramethylpyrazine phosphate tablets in vivo. ( Guo, L; Sun, Y; Wang, A; Xu, C, 2012)
"Ranolazine (RAN) was reported to be effective and safe in converting atrial fibrillation (AF) to sinus rhythm by administration of a single dose ('pill in the pocket') to patients with structural heart disease."	3.78	Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. ( Clauß, C; Eckardt, L; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Schmidt, M; Stypmann, J, 2012)
"The present study demonstrated prophylactic and therapeutic potential of Terminalia arjuna bark extract in isoproterenol (ISO)-induced chronic heart failure (CHF)."	3.77	Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. ( Agarwal, S; Babbar, R; Fahim, M; Kotwani, A; Parveen, A, 2011)
"Heart failure was induced by isoproterenol in male Sprague-Dawley rats."	3.77	Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. ( Cai, H; Cao, SP; Gu, N; Qian, CF; Song, YH; Zhao, ZM, 2011)
"The effect of atorvastatin on cardiac remodeling, function, and homodynamic parameters in isoproterenol-induced heart failure was evaluated in the present study."	3.77	Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. ( Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H, 2011)
" Isoproterenol (ISO) infusion can accelerate cardiomyopathy in young SHHFs, while dietary salt loading in hypertensive rats induces cardiac fibrosis, hypertrophy, and--in a minority-congestive HF."	3.77	Dietary salt exacerbates isoproterenol-induced cardiomyopathy in rats. ( Carll, AP; Costa, DL; Farraj, AK; Haykal-Coates, N; Hazari, MS; Nyska, A; Richards, JH; Willis, MS; Winsett, DW, 2011)
" The heart failure model was induced by injection of isoproterenol (ISO) 340 mg/kg continuously two days."	3.77	Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats. ( Li, Y; Qu, XF; Song, Y; Sun, SQ; Wang, SJ; Wang, XT; Yu, Y, 2011)
"To find a more excellent large-dose isoproterenol (ISO) induced heart failure (HF) rat model."	3.76	The study of ISO induced heart failure rat model. ( Feng, W; Li, W, 2010)
"The aim of this study was to determine if CPU228, a derivative of dofetilide, is more effective than dofetilide in attenuating isoproterenol-induced heart failure by recovering downregulated FK506 binding protein (FKBP12."	3.76	CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C epsilon in the myocardium. ( Dai, DZ; Dai, Y; Hamed, KH; Hu, C; Yu, F, 2010)
"the aim of this study was to determine whether depressive symptoms are related to alterations in the sensitivity of peripheral blood mononuclear cells to β-adrenergic agonists in patients with heart failure (HF) by measuring in vitro chemotaxis (CTX) to isoproterenol at rest and after acute exercise in patients with HF and controls."	3.76	Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients. ( Bosch, J; Bosch, JA; Greenberg, B; Hong, S; Mills, PJ; Redwine, LS; Wirtz, PH; Ziegler, MG, 2010)
"By mimicking sympathetic stimulation in vivo, we previously reported that mice globally lacking serotonin 5-HT(2B) receptors did not develop isoproterenol-induced left ventricular hypertrophy."	3.75	Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. ( Blaxall, BC; Bonnin, P; Callebert, J; Debbabi, H; Doly, S; Jaffré, F; Launay, JM; Maroteaux, L; Mettauer, B; Monassier, L; Setola, V, 2009)
"Our study demonstrates the contribution of IL-17 to myocardial fibrosis in isoproterenol-induced HF."	3.75	IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. ( Feng, W; Li, W; Li, Y; Liu, W; Wang, F; Yan, W, 2009)
"Transgenic (TG) Ca/calmodulin-dependent protein kinase II (CaMKII)delta(C) mice have heart failure and isoproterenol (ISO)-inducible arrhythmias."	3.75	Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. ( Abesser, M; Backs, J; Brown, JH; Grefe, C; Khabbazzadeh, S; Maier, LS; Maier, SK; Neef, S; Neumann, K; Olson, EN; Opiela, MK; Sag, CM; Wadsack, DP, 2009)
"Isoproterenol-induced cardiac hypertrophy in mice has been used in a number of studies to model human cardiac disease."	3.75	Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. ( Errami, M; Galindo, CL; Garner, HR; Kumar, NM; Li, J; McCormick, JF; McIver, LJ; Olson, LD; Pham, TQ; Skinner, MA; Watson, DA, 2009)
"A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure."	3.74	Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008)
"To study the treatment effect of Wenxin Keli on isoproterenol (ISO) induced heart failure in rats."	3.74	[Protection effect of Wenxin Keli on isoproterenol induced heart failure in rats]. ( Hu, SJ; Mu, Y; Zhou, F, 2007)
" Similarly, adult beta1KOmdx males were more prone to isoproterenol-induced heart failure and death compared with control groups."	3.74	Combined deficiency of dystrophin and beta1 integrin in the cardiac myocyte causes myocardial dysfunction, fibrosis and calcification. ( Chu, AL; Chun, J; Elsherif, L; Huang, MS; Kaufman, SJ; Li, RY; Mekany, MA; Ross, RS; Shai, SY; Yang, Y, 2008)
"Heart failure (HF) may be produced by sustained beta-adrenoceptor stimulation by causing changes in the expression of endothelin-1 (ET-1), the leptin system, calcineurin and sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) underlying cardiac dysfunction."	3.74	Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats. ( Dai, DZ; Dai, Y; Ji, H; Tang, XY; Xu, M, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."	3.73	Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol."	3.73	Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005)
"Hyperphosphorylation of the cardiac Ca2+ release channel (ryanodine receptor, RyR2) by protein kinase A (PKA) at serine-2808 has been proposed to be a key mechanism responsible for cardiac dysfunction in heart failure (HF)."	3.73	Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. ( Chen, SR; Cheng, H; Jiang, MT; Lai, FA; Sutherland, C; Walsh, MP; Warltier, DC; Xiao, B; Yang, D; Zhao, M, 2005)
"Our results suggest that PDE3A reduction and consequent inducible cAMP early repressor induction are critical events in Ang II- and isoproterenol-induced cardiomyocyte apoptosis and may contribute to the development of heart failure."	3.73	Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. ( Abe, JI; Berk, BC; Blaxall, BC; Ding, B; Huang, Q; Molina, CA; Sadoshima, J; Walsh, RA; Wei, H; Yan, C; Zhao, A, 2005)
"To evaluate the hemodynamic effects of orally administered carvedilol in healthy dogs with doses that might be used to initiate treatment in dogs with congestive heart failure."	3.73	Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. ( Abbott, JA; Broadstone, RV; Pyle, RL; Ward, DL, 2005)
"The role of phosphorylation of the ryanodine receptor at serine-2808 (RyRS2808) in congestive heart failure (CHF) is controversial, and effects of RyRS2808 phosphorylation on contraction are unclear."	3.73	Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. ( Chen, SR; Davidoff, AW; Mei, J; Obayashi, M; Stuyvers, BD; ter Keurs, HE; Xiao, B, 2006)
"The purpose of present study was to investigate the effect of metabolic substrate pyruvate and beta-adrenergic agonist isoproterenol and combination of these agents on the force- and relaxation-frequency relationship in human heart failure."	3.73	The force-frequency relationship in human heart failure: effect of pyruvate and isoproterenol. ( Gendviliene, V; Gurskaite, H; Martisiene, I; Zablockaite, D, 2005)
" A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction."	3.73	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. ( Deres, P; Gallyas, F; Halmosi, R; Hanto, K; Hideg, K; Kalai, T; Kulcsar, G; Palfi, A; Sumegi, B; Szabados, E; Szereday, Z; Toth, A; Toth, K, 2006)
"Animals with heart failure exhibited depressions in ventricular function, positive inotropic response to isoproterenol, beta-AR receptor density and basal AC activity; these changes were also attenuated by PLC treatment."	3.72	Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. ( Dhalla, NS; Ferrari, R; Sethi, R; Wang, X, 2004)
"These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure."	3.72	Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004)
"Several clinical trials have demonstrated that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1 receptor blocker (ARB) are equally effective in the treatment of chronic heart failure."	3.72	Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. ( Hasebe, N; Izawa, K; Jin, YT; Kido, S; Kikuchi, K; Natori, S; Ohta, T; Sato, M; Tsuji, S, 2004)
"Furosemide shortened the time to left ventricular dysfunction (35."	3.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
" In a randomized prospective trial design, we administered the XO inhibitor allopurinol orally to mice that had undergone massive myocardial infarction (MI)."	3.72	Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. ( Gao, WD; Leppo, MK; Marbán, E; Stull, LB; Szweda, L, 2004)
"We measured cardiac conformation, contractile performance and cytokines level in 8 age-matched normal adult rats (control group) and 8 rats with isoproterenol (ISO)-induced Heart failure (ISO group) and 8 rats with ISO-induced lesion but received EB treatment (EB group)."	3.71	Chronic treatment of enbrel in rats with isoproterenol-induced congestive heart failure limits left ventricular dysfunction and remodeling. ( Gan, R; Li, W; Sun, G, 2002)
"To corroborate alterations in the functional responses to beta-adrenergic receptor (beta-AR) stimulation with changes in beta-AR signaling in failing cardiomyocytes, contractile and L-type Ca(2+) current responses to isoproterenol along with stimulated cAMP generation were compared among cardiomyocytes isolated from canines with tachycardia-induced heart failure or healthy hearts."	3.71	Functional desensitization to isoproterenol without reducing cAMP production in canine failing cardiocytes. ( Armour, JA; Bouchard, C; Bouvier, M; Cardinal, R; Laurent, CE; Rousseau, G; Vermeulen, M; Wilkinson, M, 2001)
"In rats, a toxic dosage of isoproterenol caused characteristic myocardial damage that subsequently resulted in mild heart failure."	3.70	Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. ( Bruckschlegel, G; Elsner, D; Griese, D; Grimm, D; Kromer, EP; Muders, F; Pfeifer, M; Riegger, GA; Schunkert, H, 1998)
"Long-term metoprolol therapy improves cardiac performance and decreases mortality in patients with chronic congestive heart failure (CHF)."	3.70	Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. ( DiBona, GF; Sawin, LL, 1999)
"We recently demonstrated that rapid ventricular pacing caused cardiac failure (Failure) in dogs with aortic stenosis-induced left ventricular hypertrophy (Hypertrophy) and isoproterenol caused no significant increases in function, O2 consumption and intracellular cyclic AMP level in the failing hypertrophied hearts."	3.70	Down regulation of myocardial beta1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy. ( He, YQ; Huang, MW; Leone, RJ; Scholz, PM; Tse, J; Weiss, HR, 2000)
"We conclude that endogenous catecholamines, acting via beta 2-adrenergic receptors, attenuate the permeability response to histamine in pacing-induced heart failure."	3.70	Attenuation of histamine-induced endothelial permeability responses after pacing-induced heart failure: role for endogenous catecholamines. ( Dougherty, FC; Dyess, DL; Hunter, JL; Lakey, JR; Moyer, D; Townsley, MI, 2000)
"We examined the dose responses to continuous infusion of isoproterenol (ISO) and norepinephrine (NE) in normal (control) and procainamide-induced heart failure dogs with or without inhalation of 70 ppm nitric oxide (NO)."	3.70	Effect of inhaled nitric oxide on cardiovascular response to catecholamine in heart failure. ( Hasebe, N; Ido, A; Jin, Y; Kikuchi, K; Matsuhashi, H; Matsusaka, T; Morihira, M; Nakamura, H; Natori, S; Ohta, T; Tsuji, S, 2000)
" To examine the status of beta-adrenergic receptors and postadrenergic receptor mechanisms in congestive heart failure due to myocardial infarction, the left coronary artery in rats was ligated for 4 and 8 weeks before studying the hemodynamic and biochemical changes due to isoproterenol, a beta-adrenoceptor agonist, or forskolin, a postreceptor agonist."	3.69	Inotropic responses to isoproterenol in congestive heart failure subsequent to myocardial infarction in rats. ( Dhalla, NS; Sethi, R, 1995)
" To investigate whether inotropic responsiveness is associated with alterations in beta-adrenergic receptors in spontaneously hypertensive rats (SHR), we studied left ventricular myocardial contractile responses to isoproterenol and beta-adrenergic receptor density and affinity in age-matched rats (18 to 24 months), including SHR without heart failure, SHR with evidence of heart failure, and normotensive control Wistar-Kyoto rats (WKY)."	3.69	Modulation of left and right ventricular beta-adrenergic receptors from spontaneously hypertensive rats with left ventricular hypertrophy and failure. ( Atkins, FL; Bing, OH; Brooks, WW; Conrad, CH; DiMauro, PG; Robinson, KG, 1995)
"The present study compared the effects of amrinone, dobutamine, dibutyryl cAMP, digoxin, and isoproterenol on mechanical performance, the high energy phosphate metabolites, and the [Ca2+]i transients in normal and cardiomyopathic hamster hearts with severe heart failure."	3.69	Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts. ( Buser, PT; Jasmin, G; Parmley, WW; Wikman-Coffelt, J; Wu, SY, 1995)
"The enhanced sensitivity of the failing human myocardium towards Na(+)-channel modulation is not due to a direct or indirect interaction of (+/-)BDF 9148 with cardiac myofilaments but may be due to an altered Na(+)-homeostasis in human heart failure."	3.69	Increase in force of contraction by activation of the Na+/Ca(2+)-exchanger in human myocardium. ( Brixius, K; Frank, K; Müller-Ehmsen, J; Schwinger, RH, 1997)
" A significant reversal of cardiac failure was attained in anaesthetised dogs subjected to propranolol induced cardiac insufficiency."	3.68	Cardiotonic activity of the water soluble forskolin derivative 8,13-epoxy-6 beta-(piperidinoacetoxy)- 1 alpha, 7 beta, 9 alpha-trihydroxy-labd- 14en-11-one. ( Ghate, AV; Linz, W; Rajagopalan, R; Schoelkens, BA; Subbarayan, P, 1993)
"During a 3-year period we administered enoximone, a phosphodiesterase inhibitor with positive inotropic and vasodilator properties, to 73 pretransplantation patients with end-stage heart failure who exhibited a clinical requirement for additional inotropic support."	3.68	Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors. ( Gilbert, EM; Hershberger, RE; Lee, HR; Mealey, PC; Menlove, R; O'Connell, JB; Port, JD; Rasmussen, R; Renlund, DG; Volkman, K, 1991)
"The effects on ventricular function of calcium channel blockers and isoproterenol were studied in isovolumically beating perfused control rabbit hearts and in hearts subjected to a double pressure plus volume overload studied at the early phase of heart failure."	3.68	Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. ( Crozatier, B; el Houda Bouanani, N; Ezzaher, A; Hittinger, L; Su, JB, 1991)
"The aim was to investigate the pattern of release of atrial natriuretic factor induced by mechanical and adrenergic stimulation from atria of rats with or without congestive heart failure."	3.68	Effect of congestive heart failure on rate of atrial natriuretic factor release in response to stretch and isoprenaline. ( Agnoletti, G; Cornacchiari, A; De Giuli, F; Ferrari, R; Ghielmi, S; Panzali, AF, 1990)
"Cardiac hypertrophy and failure were induced in male Wistar rats by daily administration of 5 mg/kg isoproterenol for three weeks."	3.68	Ultrastructural and electrophysiological alterations during the development of catecholamine-induced cardiac hypertrophy and failure. ( Lévai, G; Mészáros, J, 1990)
"1 The responses to substance P, isoprenaline and noradrenaline were observed on human isolated coronary arteries removed from 30 human hearts, and were classified according to the age of the hearts, the presence or absence of cardiac failure and the degree of atherosclerosis."	3.67	The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline. ( Berkenboom, G; Depierreux, M; Fontaine, J, 1987)
"The positive inotropic effect of milrinone was investigated in isolated, electrically driven (1 Hz) human papillary muscle strips from nonfailing myocardium (control) and from patients with moderate (NYHA II-III) and severe (NYHA IV) heart failure."	3.67	Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart. ( Böhm, M; Diet, F; Erdmann, E; Kemkes, B, 1988)
"Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were investigated."	3.67	[Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs]. ( Sonoki, H; Sugimoto, T; Tomaru, T; Uchida, Y, 1988)
"Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption."	3.67	Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985)
"Thirty-one age-matched, conscious, virgin, male Sprague-Dawley rats and spontaneously hypertensive rats (SHRs) were individually injected with a single subcutaneous dose of 85 mg/kg dl-isoproterenol to determine the degree and time course of drug-induced cardiac failure and functional recovery."	3.66	Isoproterenol-induced cardiac failure in the spontaneously hypertensive rat. ( Iams, SG; Yeager, JC, 1981)
"Hemodynamic responses to propranolol and isoproterenol were examined in elderly patients with heart failure."	3.66	Studies on heart failure in old age (Part II). Hemodynamic effects of propranolol and isoproterenol in elderly patients with heart failure. ( Mifune, J, 1978)
"The inotropic response of the left ventricle to intravenous administration of norepinephrine (NE) and isoproterenol (I) was studied in dogs with congestive heart failure (CHF) resulting from aortocaval fistula."	3.65	A depressed response of left ventricular contractile force to isoproterenol and norepinephrine in dogs with congestive heart failure. ( Newman, WH, 1977)
"Dobutamine was infused at a rate of 8 mcg/kg/min in 17 patients with or without congestive heart failure."	3.65	Comparative haemodynamic effects of dobutamine and isoproterenol in man. ( Bardet, J; Boschat, J; Bourdarias, JP; Ferreira, A; Rigaud, M; Rocha, P, 1977)
" In the absence of cardiac glycoside, the only demonstrable abnormalities of sinus node function were mild resting sinus bradycardia and failure to respond to atropine administration."	3.65	Digitalis and the sick sinus syndrome. Clinical and electrophysiologic documentation of severe toxic effect on sinus node function. ( Gilbert, M; Margolis, JR; Miller, HC; Strauss, HC; Wallace, AG, 1975)
" This review summarizes the results of studies carried out by our group of the effect of astaxanthin (AST) on the functional state of rat heart mitochondria upon direct addition of AST to isolated mitochondria and upon chronic administration of AST under conditions of mPTP opening."	2.72	Mitochondrion as a Target of Astaxanthin Therapy in Heart Failure. ( Baburina, Y; Krestinin, R; Krestinina, O, 2021)
"Heart failure is a problem of increasing importance in cardiovascular medicine."	2.39	Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. ( Koch, WJ; Lefkowitz, RJ; Milano, CA; Rockman, HA, 1996)
"Cardiac fibrosis is an essential structural remodeling associated with HF; therefore, preventing cardiac fibrosis is crucial to decelerating the progression of HF."	1.91	Sodium houttuyfonate against cardiac fibrosis attenuates isoproterenol-induced heart failure by binding to MMP2 and p38. ( Adu-Amankwaah, J; An, K; Cui, J; Lin, L; Song, N; Sun, H; Tan, R; Wang, M; You, Q; Yuan, J, 2023)
"Cardiac hypertrophy was induced in rats by subcutaneous injection of isoproterenol (ISO, 1."	1.91	JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit. ( Cai, SD; Feng, GS; Guo, Z; Hu, YH; Javaheri, A; Li, Q; Li, ZZ; Liang, LY; Liu, PQ; Lu, J; Luo, WW; Valenzuela Ripoll, C; Wang, L; Wang, QQ; Wu, ZK; Zhang, JG, 2023)
"Echinacoside (ECH) is a natural phenylethanoid glycoside and is the major active component of traditional Chinese medicine Cistanches Herba, which is reported to possess powerful anti-oxidation and anti-inflammatory effects."	1.72	Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress. ( Bai, H; Duan, Y; Luan, C; Ni, Y; Zhang, J; Zhu, W, 2022)
"Ferulic acid (FA) has potential therapeutic effects in multiple diseases including cardiovascular diseases."	1.62	Ferulic Acid Ameliorates Isoproterenol-Induced Heart Failure by Decreasing Oxidative Stress and Inhibiting Cardiocyte Apoptosis via Activating Nrf2 Signaling Pathway in Rats. ( Cui, ZH; He, TT; Liang, XW; Wang, L; Zhang, XJ; Zhao, YX, 2021)
"Recent data show that cardiac hypertrophy contributes substantially to the overall heart failure burden."	1.56	STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. ( Ke, Q; Liu, B; Liu, F; Mei, Y; Su, H; Sun, X; Tan, W, 2020)
"Mangiferin is a well-known xanthone extracted from mango leaves (Mangifera indica Linn)."	1.56	Mangiferin exert cardioprotective and anti-apoptotic effects in heart failure induced rats. ( Gao, G; Han, F; Jiang, T; Liu, M, 2020)
"It was found that SMYAD could regulate cardiac hypertrophy and fibrosis makers' mRNA levels in vitro and vivo."	1.56	Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure. ( Chen, Y; Jiang, Y; Yao, X; Zhang, F; Zhang, X; Zhao, Y; Zhu, L, 2020)
"Isoproterenol (ISO), is a non-selective beta-adrenergic agonist, that is used widely to induce cardiac injury in mice."	1.51	Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice. ( Chang, S; Mandelli, A; Ren, S; Tran, A; Wang, JJ; Wang, Y, 2019)
" A histological analysis revealed that chronic intake of MEL diminished the age-dependent changes in the structure of muscle fibers of the left ventricle, muscle fiber swelling, and injury zones characteristic of acute cardiac failure caused by ISO."	1.48	Effect of Melatonin on Rat Heart Mitochondria in Acute Heart Failure in Aged Rats. ( Akatov, V; Baburina, Y; Fadeeva, I; Krestinina, O; Kruglov, A; Odinokova, I; Sotnikova, L; Zvyagina, A, 2018)
"The treatment of cycloastragenol improved deranged cardiac parameters in the isoproterenol-induced heart damage model in a dose-dependent manner."	1.48	Cycloastragenol ameliorates experimental heart damage in rats by promoting myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling. ( Cai, H; Cao, SP; Song, YH; Wang, J; Wu, ML; Zhao, ZM, 2018)
" Cardio toxic rat model was induced by subcutaneous administration of Isoproterenol (ISO) (30mg/kg) for two consecutive days in adult male rats."	1.46	In vivo ameliorative effect of cerium oxide nanoparticles in isoproterenol-induced cardiac toxicity. ( Abdelazim, SM; El Shaer, SS; Saied, NM; Salaheldin, TA, 2017)
"Fusaric acid (FA) is a novel compound derived from a class of nicotinic acid derivatives, exhibiting activity against cancers."	1.46	Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways. ( Li, X; Wang, HF; Zhang, ZL, 2017)
"Isoproterenol (ISO) has been widely used to establish cardiac injury in vivo and in vitro."	1.46	Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress. ( Chen, DL; Wang, Z; Yang, J, 2017)
"Type 2 diabetes mellitus is a complex metabolic disease, and cardiovascular disease is a leading complication of diabetes."	1.43	Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes. ( Antunes, M; Burgeiro, A; Carvalho, E; Carvalho, RA; Cherian, S; Espinoza, D; Fuhrmann, A; Jarak, I; Loureiro, M; Patrício, M, 2016)
"To evaluate the role of miR-99a in cardiac hypertrophy, we assessed the expression of miR-99a in hypertrophic cardiomyocytes induced by isoprenaline (ISO)/angiotensin-II (Ang II) and in mice model of cardiac hypertrophy induced by transverse aortic constriction (TAC)."	1.43	Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy. ( Bai, J; Ding, L; Gu, R; Li, Q; Li, R; Wang, B; Wang, L; Xie, J; Xu, B, 2016)
"Cardiac fibrosis is a common feature of advanced coronary heart disease and is characteristic of heart disease."	1.42	A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway. ( Bai, Y; Fan, TP; Li, Z; Lu, H; Tian, A; Wu, J; Yang, C; Yang, Q; Yin, Q; Zhang, Y; Zheng, X, 2015)
"Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes."	1.42	Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015)
"Isoproterenol was administered twice to female Wistar rats (170 mg/kg, s."	1.39	Ventricular repolarization in a rat model of global heart failure. ( Kharin, S; Krandycheva, V; Shmakov, D; Shumikhin, K; Sobolev, A; Strelkova, M, 2013)
"The epidemic of heart failure has stimulated interest in understanding cardiac regeneration."	1.39	Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. ( Agosti, V; Aquila, I; Condorelli, G; Ellison, GM; Henning, BJ; Indolfi, C; Leone, A; Nadal-Ginard, B; Ottolenghi, S; Papait, R; Scarfò, M; Smith, AJ; Stirparo, GG; Torella, D; Vicinanza, C; Viglietto, G; Waring, CD, 2013)
"Heart failure was induced by isoprenaline s."	1.39	Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. ( Cai, Z; Chen, C; Cianflone, K; Duan, Q; Gong, W; Ni, L; Wang, DW; Wang, X; Yan, M, 2013)
"In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3."	1.39	Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. ( Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM, 2013)
"Our data showed that ISO treatment led to heart failure in OVX rats."	1.38	Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. ( Hao, Y; Kang, S; Li, D; Liu, A; Liu, Y; Sun, D; Sun, H; Xu, C; Yan, C; Zhou, C, 2012)
" Isoprenaline (ISO), a β-adrenoceptor agonist, was infused at variable dosage and duration using either subcutaneously implanted osmotic minipumps or daily injections, in an attempt to establish the relevant treatment protocol."	1.37	Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation. ( Olesen, SP; Osadchii, OE; Soltysinska, E, 2011)
"Chronic isoproterenol (ISO)-induced cardiac hypertrophy was inhibited in wild-type mice and AT1aR(-/-) mice treated with the ARB Candesartan (CV11974)."	1.36	Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors. ( Kimura, S; Matsuyoshi, H; Murao, K; Obata, K; Takaki, M; Yu, X; Zhang, GX, 2010)
"The extent of heart failure has been estimated by supersonic inspection 28 and 60 days after isoproterenol injections."	1.35	[The density of myocardial and pericardial rat mast cells in isoproterenol-induced heart failure]. ( Emel'ianova, OI; Erokhina, IL; Kazachenko, AA; Kulikov, AN; Martynova, MG; Moiseeva, OM; Okovityĭ, SV; shulenin, SN, 2008)
"Global heart failure was induced in Wistar rats by isoproterenol injection."	1.35	Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. ( Guan, Z; Li, L; Li, Y; Xu, Y; Yu, B; Zhang, Y; Zhao, S, 2008)
"In isoprenaline-treated rats, cardiac hypertrophy and dysfunction were found."	1.35	Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. ( Cheng, YS; Dai, DZ; Dai, Y, 2009)
"Rats with congestive heart failure (CHF) develop ventricular inotropic responsiveness to serotonin (5-HT), mediated through 5-HT(2A) and 5-HT(4) receptors."	1.34	Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes. ( Birkeland, JA; Enger, U; Levy, FO; Lunde, PK; Qvigstad, E; Sejersted, OM; Sjaastad, I; Swift, F; Tovsrud, N, 2007)
"Strophanthidin toxicity was dependent on concentration, calcium load, beating rate and beta-adrenergic receptor activation."	1.34	Mechanistic insight into the functional and toxic effects of Strophanthidin in the failing human myocardium. ( Bisping, E; Elgner, A; Kockskämper, J; Pieske, B; von Lewinski, D, 2007)
"Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist."	1.33	Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005)
"Two murine models of cardiac hypertrophy confirmed upregulation of PLCepsilon protein expression or PLCepsilon RNA."	1.33	Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. ( Blaxall, BC; Bullard, TA; Dirksen, RT; Kelley, GG; Maekawa, N; Oestreich, EA; Smrcka, AV; Vikstrom, KL; Wang, H, 2005)
" After the dose-response curve was obtained, the author measured the inotropic response to 1 micromol/L of isoproterenol in the presence of the cumulative dose of remifentanil."	1.33	Effects of remifentanil on the contractility of failing human heart muscle. ( Moravec, CS; Ogletree, ML; Sprung, J, 2005)
"Because heart failure is a progressive disease that often evolves from hypertrophy, we analyzed the RyR2 macromolecular complex in several animal models of cardiomyopathy that lead to heart failure, including hypertrophy, and at different stages of disease progression."	1.32	Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. ( Burkhoff, D; D'Armiento, J; Gaburjakova, M; Gomez, AM; Guatimosim, S; Lederer, WJ; Marks, AR; Reiken, S; Vassort, G; Wang, J, 2003)
"Chronic heart failure was induced in male Wistar rats by coronary artery ligation."	1.32	Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Sandnes, D; Schiander, I; Sejersted, OM; Sjaastad, I; Sjetnan, A; Skomedal, T, 2003)
"The isoproterenol-stimulated increase in I Ca(L) was significantly smaller in postinfarction myocytes (Emax: 63."	1.32	Impaired beta-adrenergic response and decreased L-type calcium current of hypertrophied left ventricular myocytes in postinfarction heart failure. ( Chedid, NG; Díaz G, LE; Masuda, MO; Quintero H, CC; Saraiva, RM, 2003)
"Since heart failure is also associated with attenuated responses to catecholamines, we examined the effects of imidapril, an ACE inhibitor, on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart."	1.32	Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. ( Dhalla, NS; Ren, B; Saini, HK; Sethi, R; Shao, Q; Takeda, N, 2004)
"Selegiline is a centrally acting sympatholytic agent with neuroprotective properties."	1.31	Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure. ( Dong, E; Kawai, H; Liang, CS; Shite, J; Stevens, SY, 2000)
"V-O cardiac hypertrophy was induced in rabbits by the formation of an arterio-venous shunt between the carotid artery and jugular vein 12 to 15 weeks after the operation."	1.31	Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes. ( Atsumi, H; Endoh, M; Nakada, S; Sakurai, K; Sugawara, H; Tomoike, H, 2000)
"Ventricular arrhythmias and contractile dysfunction are the main causes of death in human heart failure (HF)."	1.31	Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. ( Bers, DM; Li, L; Pogwizd, SM; Schlotthauer, K; Yuan, W, 2001)
"Levosimendan has been reported to increase cardiac Ca(2+) sensitivity, thereby not enhancing intracellular Ca(2+) or diastolic tension."	1.31	Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. ( Brixius, K; Reicke, S; Schwinger, RH, 2002)
"ACF induced cardiac hypertrophy in rats with compensated (36%) and decompensated (76%) HF."	1.31	Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. ( Abassi, Z; Binah, O; Gealekman, O; Rubinstein, I; Winaver, J, 2002)
"Heart failure is associated with alterations in contractile parameters and accompanied by abnormalities in intracellular calcium homeostasis."	1.31	Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. ( Bøkenes, J; Christensen, G; Hoen, IB; Holt, E; Lunde, PK; Sande, JB; Sjaastad, I; Tønnessen, T, 2002)
"Propofol has a direct and negative effect on basal myocyte contractile processes in the setting of CHF, which is more pronounced than that on healthy myocytes at reduced propofol concentrations."	1.30	Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing-induced congestive heart failure. ( Clair, MJ; Dorman, BH; Hebbar, L; Roy, RC; Spinale, FG, 1997)
"Two signatures of heart failure are activation of the sympathetic nervous system and catecholamine desensitization."	1.30	Effects of cardiac denervation on development of heart failure and catecholamine desensitization. ( Asai, K; Ghaleh-Marzban, B; Kudej, RK; Mirsky, I; Patrick, TA; Sato, N; Shannon, RP; Shen, YT; Uechi, M; Vatner, DE; Vatner, SF, 1997)
"Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents."	1.30	The effect of positive inotropes on the failing human myocardium. ( Erdmann, E, 1997)
"The objective of this study was to assess the structural, mechanical and electrophysiological changes associated with chronic administration of epirubicin (Pharmorubicin), which is a cardiotoxic anthracycline antibiotic used in conventional cancer chemotherapy."	1.30	Characterisation of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline, epirubicin. ( Cameron, CH; Geraghty, RF; Kelso, EJ; McDermott, BJ; Nicholls, DP; Silke, B, 1997)
"The development of congestive heart failure (CHF) is accompanied by left ventricular (LV) and myocyte contractile dysfunction."	1.30	Changes in L-type calcium channel abundance and function during the transition to pacing-induced congestive heart failure. ( Basler, CG; Hewett, KW; Mukherjee, R; Spinale, FG; Walker, JD, 1998)
"Heart failure was documented by decreased LV fractional shortening (P < 0."	1.30	Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure. ( Anzai, T; Gao, M; Hammond, HK; Lai, NC, 1998)
"Heart failure is associated with activation of cytokines and expression of inducible nitric oxide synthase (NOS II), which generates NO from L-arginine."	1.30	Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. ( Brodde, OE; Drexler, H; Hasenfuss, G; Kästner, S; Strobel, A; Studer, R, 1998)
"Caffeine (10 mM) was used to release calcium from the SR."	1.30	Effects of cyclic adenosine monophosphate (cAMP) on sarcoplasmic reticulum Ca(2+)-loading in failing rabbit and human cardiac trabeculae. ( Cobbe, SM; Denvir, MA; MacFarlane, NG; Miller, DJ, 1998)
"If operative in patients with congestive heart failure (CHF), such receptors could participate in positive feedback cycles amplifying sympathoactivation."	1.30	Regulation of regional norepinephrine spillover in heart failure: the effect of angiotensin II and beta-adrenergic agonists in the forearm circulation. ( Garr, M; Goldsmith, SR; McLaurin, M, 1998)
"The propranolol treated animals had higher LV end-diastolic pressures (27+/-2* vs 20+/(-3 mmHg) and a more restricted LV diastolic filling pattern (increased ratio of early to late filling velocities and more rapid E wave deceleration rate)."	1.30	Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. ( Douglas, PS; Katz, SE; Litwin, SE; Morgan, JP, 1999)
"Mibefradil treatment increased MAP and dP/dtmax and decreased LVEDP and HR in infarcted rats."	1.30	Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats. ( Meissner, A; Min, JY; Sandmann, S; Unger, T, 1999)
"Dantrolene sodium is a clinically used drug that modulates myocardial [Ca2+]i handling in animal models."	1.30	Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium. ( Haake, N; Hirt, S; Meissner, A; Min, JY; Simon, R, 1999)
"DL-Sotalol has class III antiarrhythmic activity through prolongation of the repolarization phase of the action potential as well as beta-adrenoceptor-blocking properties."	1.29	Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. ( Fraedrich, G; Hasenfuss, G; Holubarsch, C; Just, H; Pieske, B; Posival, H; Ruf, T; Schneider, R, 1995)
"Heart failure was induced by experimental infarction in 17 normotensive male Wistar rats; 14 rats were sham operated."	1.29	Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. ( de Graeff, PA; de Smet, BG; Monnink, S; Pinto, YM; Scholtens, E; van Gilst, WH; Wesseling, H, 1993)
"The extent to which congestive heart failure (CHF) is dependent upon increased levels of the cardiac inhibitory GTP-binding protein (Gi), and the impact of CHF on the cardiac stimulatory GTP-binding protein (Gs) and mechanisms by which Gs may change remain unexplored."	1.29	Downregulation of cardiac guanosine 5'-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure. ( Hammond, HK; Helmer, GA; Roth, DA; Urasawa, K, 1993)
"Dopexamine is a synthetic catecholamine with predominantly beta 2 and dopaminergic adrenergic receptor activities."	1.29	Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs. ( Rogers, BW; Sziszak, TJ; Sziszak, TL; Taylor, BJ, 1993)
"Carbachol abolished the increase in light transients and cAMP accumulation induced by Org 30029 (1 mM), whereas it only partially attenuated the positive inotropic effect of Org 30029."	1.29	Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. ( Endoh, M; Kawabata, Y, 1993)
" Dose-response curves plotted as percentage change from baseline versus concentration of drug were determined for acetylstrophanthidin, isoproterenol, isobutylmethylxanthine, and milrinone."	1.29	Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium. ( Bruce, E; Flemmal, K; Grossman, W; Gutstein, DE; Gwathmey, JK; Markis, JE; Morgan, JP; Ransil, BJ; Travers, KE, 1996)
"Treatment with captopril for 5 weeks, beginning 1 week after infarction (n = 14), resulted in reduction of left ventricular filling pressures and partial normalization of myocardial contractility and Ca2+i handling."	1.28	Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. ( Litwin, SE; Morgan, JP, 1992)
"Digoxin caused an increase in end-diastolic pressure in myopathic and chronic alcohol hearts but not control hearts."	1.28	Activation of glycolysis with isoproterenol but not digoxin reverses chronic alcohol depression in hamster hearts. ( Auffermann, W; Buser, P; Parmley, WW; Wikman-Coffelt, J; Wu, S, 1992)
" Tension generation and dT/dt observed in the paced dogs in response to increasing concentrations of forskolin demonstrated a rightward shift in the dose-response curve and a decrease in maximal forskolin stimulation (p less than 0."	1.28	Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. ( Bouvier, M; Calderone, A; de Champlain, J; Juneau, C; Li, K; Rouleau, JL, 1991)
"The degree of heart failure affected neither the potency (EC50: control: 0."	1.28	Different beta-adrenoceptor-effector coupling in human ventricular and atrial myocardium. ( Böhm, M; Erdmann, E; Pieske, B; Schwinger, RH, 1991)
" Furthermore, the dose-response relation to isoproterenol was similar in both groups."	1.28	Limb vascular responsiveness to beta-adrenergic receptor stimulation in patients with congestive heart failure. ( Colucci, WS; Creager, MA; Quigg, RJ; Ren, CJ; Roddy, MA, 1991)
"Xamoterol was considerably less effective than isoproterenol in stimulating adenylate cyclase activity but the difference was narrowed by 1 microM forskolin, presumably by inducing more efficient coupling to the catalytic subunit of the enzyme."	1.28	Effects of xamoterol on the reversible cycling of cardiac beta-adrenoceptors. ( Limas, C; Limas, CJ, 1990)
"Induction of congestive heart failure in a paced canine model resulted in alterations in the autonomic profile that resembled those seen in humans with ventricular failure."	1.28	Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. ( Binkley, PF; Cody, RJ; Haas, GJ; Nelson, SD; Nunziata, E, 1991)
"Captopril treatment led to an up-regulation of cardiac beta 1- but not mononuclear leukocyte beta 2-adrenergic receptors and an increase in isoproterenol-stimulated adenylate cyclase activity in the heart."	1.28	Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. ( Carter, SM; Maisel, AS; Michel, MC; Phillips, C; Ziegler, MG, 1989)
"Chronic treatment of heart failure patients with beta-adrenoceptor antagonists leads to an up-regulation of cardiac beta-adrenoceptors, but in a subtype-selective fashion: beta 1-selective antagonists increase only cardiac beta 1-adrenoceptors, whereas non-selective antagonists increase both beta 1- and beta 2-adrenoceptors."	1.28	Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. ( Borst, HG; Brodde, OE; Maier, W; Michel, MC; Zerkowski, HR, 1989)
"Adenosine is a metabolic coronary vasodilator [1] and also has recently been shown to antagonize the inotropic action of beta-adrenergic agonists through a mechanism involving action on the sarcolemmal adenylate cyclase system [4, 13]."	1.27	Increased myocardial adenosine release in heart failure. ( Frankis, MB; Grossman, SJ; Newman, WH; Webb, JG, 1984)
"The effects of congestive heart failure on the physiological and biochemical functions of the cardiac beta-adrenoceptor-coupled adenylate cyclase system were studied in dogs with right heart failure produced by progressive pulmonary artery constriction and tricuspid avulsion."	1.27	Alterations in cardiac beta-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. ( Banerjee, SP; Fan, TH; Kawashima, S; Liang, CS, 1987)
"Three patients had idiopathic dilated cardiomyopathy and one patient had inflammatory heart disease."	1.27	Increase in myocardial Gi-proteins in heart failure. ( Döring, V; Kalmar, P; Neumann, J; Schmitz, W; Scholz, H; von Meyerinck, L, 1988)
"Length-contractile force curves and dose-response curves of heart rate, blood pressure, and contractile force were recorded from the left ventricle of six anesthetized dogs in a control state."	1.26	Persistence of myocardial failure following removal of chronic volume overload. ( Newman, WH; Privitera, PJ; Webb, JG, 1982)
"The extent of cardiac failure was isoproterenol dose dependent."	1.26	The hemodynamics of isoproterenol-induced cardiac failure in the rat. ( Iams, SG; Yeager, JC, 1981)
"These observations show that "acute cardiac failure in fundamentally normal hearts" can occur after severe trauma and that treatment is possible."	1.26	[Acute heart insufficiency of primarily non-cardiac origin after polytrauma]. ( Langenstein, H; Wolff, G, 1981)
" Additionally, dose-response curves of CF in response to injected norepinephrine, isoproterenol, glucagon, and calcium were depressed when compared to the normal group while the response of heart rate and blood pressure was not different."	1.26	Volume overload heart failure: length-tension curves, and response to beta-agonists, Ca2+, and glucagon. ( Newman, WH, 1978)
" The technique used was a continuous intravenous infusion starting with an initial dosage of 3."	1.26	[Isoproterenol test in coronary failure. Comparisons with exercise stress and coronary arteriography]. ( Amard, M; Bienvenu, P; Masson, D; Morand, P; Raynaud, P, 1978)
" Particularly with the primarily cardioselective beta-stimulating agent dobutamine a marked positive inotropic effect can be achieved in a range of dosage not significantly affecting heart rate and peripheral resistance."	1.26	[Catecholamines for treatment of severe heart failure (author's transl)]. ( Kübler, W; Mäurer, W; Tillmanns, H, 1979)
"Massive myocardial infarction was then induced in intact and CCL4-treated animals."	1.26	Effect of CCL4-induced cirrhosis on the pathophysiologic course of acute myocardial infarction in nonarteriosclerotic vs arteriosclerotic male rats. ( Greenberg, BP; Wexler, BC, 1979)
"Underventilation and cardiac arrhythmias were observed only in the agonal phase after several minutes of circulatory arrest."	1.26	Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. ( Hayler, AM; Holt, DW; Medd, RK; O'Keeffe, B, 1979)
"In contrast, cardiac failure caused by volatile anesthetics proved to be resistant to this therapy."	1.25	Reversible and irreversible forms of contractile failure caused by disturbances by general anesthetics in myocardial ATP utilization. ( Höring, HJ, 1975)
"Clinical signs of congestive heart failure significantly correlated with a fall in FEV and FEF(25-75%), the development of frequency dependence of R(T), and elevation of the pulmonary wedge pressure."	1.25	Interrelation between alterations in pulmonary mechanics and hemodynamics in acute myocardial infarction. ( Hodges, M; Hyde, RW; Interiano, B; Yu, PN, 1973)

Timeframe	Studies, this research(%)	All Research%
pre-1990	196 (30.53)	18.7374
1990's	101 (15.73)	18.2507
2000's	121 (18.85)	29.6817
2010's	165 (25.70)	24.3611
2020's	59 (9.19)	2.80

Trial	Enrollment	Study Type	Start Date	Status
BAT as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence Pilot[NCT03793127]	24 participants (Actual)	Interventional	2019-01-23	Active, not recruiting
Metabolic Signalling in Muscle- and Adipose Tissue Following Insulin Withdrawal and Growth Hormone Injection in Type I Diabetes Mellitus, a Clinical Experimental Study.[NCT02077348]	9 participants (Actual)	Interventional	2014-05-31	Completed
The Role of ATGL and G0/G1 Switch Gene Complex in Lipopolysaccaride (LPS) Induced Ketosis - a Controlled, Randomised, Clinical Experimental Study[NCT02157155]	9 participants (Actual)	Interventional	2014-06-30	Completed
The Effects of Cardiac Resynchronisation Therapy on the Frank Starling Mechanism in Patients With Heart Failure[NCT05993585]	40 participants (Anticipated)	Interventional	2023-08-04	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Mitochondrion as a Target of Astaxanthin Therapy in Heart Failure. International journal of molecular sciences, 2021, Jul-26, Volume: 22, Issue:15 Topics: Drug Delivery Systems; Heart Failure; Humans; Isoproterenol; Mitochondria, Heart; Oxidation-Reductio	2021
THE EFFECTS OF DIGITALIS BODIES ON PATIENTS WITH HEART BLOCK AND CONGESTIVE HEART FAILURE. Progress in cardiovascular diseases, 1964, Volume: 6 Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Digitalis; Digitalis Glycosides; D	1964
A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochimica et biophysica acta, 2005, Aug-01, Volume: 1751, Issue:1 Topics: Animals; Calcium-Binding Proteins; Calpain; Cardiomyopathy, Dilated; Cell Membrane Permeability; Cri	2005
The role of diuretics and inotropic therapy in failure associated with myocardial infarction. Archives internationales de physiologie et de biochimie, 1984, Volume: 92, Issue:4 Topics: Acute Disease; Blood Pressure; Cardiac Complexes, Premature; Cardiotonic Agents; Chronic Disease; Di	1984
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators]. Vrachebnoe delo, 1983, Issue:10 Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Hea	1983
[Current treatment concepts in chronic heart failure]. Vutreshni bolesti, 1981, Volume: 20, Issue:2 Topics: Blood Pressure; Cyclic AMP; Dopamine; Heart Failure; Heart Rate; Hemodynamics; Humans; Isoproterenol	1981
[Catecholamines in the therapy of chronic cardiac insufficiency]. Wiener medizinische Wochenschrift (1946), 1982, Oct-15, Volume: 132, Issue:19 Topics: Cardiotonic Agents; Catecholamines; Dobutamine; Dopamine; Epinephrine; Heart Failure; Humans; Isopro	1982
Congestive heart failure in childhood and adolescence: recognition and management. American heart journal, 1983, Volume: 105, Issue:3 Topics: Adolescent; Captopril; Cardiomyopathies; Child; Digoxin; Dobutamine; Dopamine; Echocardiography; Ele	1983
[Currently used positive inotropic substances]. Therapeutische Umschau. Revue therapeutique, 1984, Volume: 41, Issue:2 Topics: Cardiotonic Agents; Chemical Phenomena; Chemistry; Coronary Disease; Dobutamine; Dopamine; Epinephri	1984
Congestive heart failure in infancy: recognition and management. American heart journal, 1982, Volume: 103, Issue:6 Topics: Acute Kidney Injury; Airway Obstruction; Anemia, Hemolytic; Arteriovenous Fistula; Asphyxia Neonator	1982
[Application of non-glycoside inotropic agents in newborn infants]. Tijdschrift voor kindergeneeskunde, 1993, Volume: 61, Issue:1 Topics: Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, D	1993
Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. Journal of molecular medicine (Berlin, Germany), 1996, Volume: 74, Issue:9 Topics: Animals; beta-Adrenergic Receptor Kinases; Cyclic AMP-Dependent Protein Kinases; Gene Expression Reg	1996
Adrenergic regulation of myocardial apoptosis. Cardiovascular research, 2000, Volume: 45, Issue:3 Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cells, Cultured; GTP-Binding Proteins; Heart Failure;	2000
Adrenergic overload and apoptosis in heart failure: implications for therapy. Journal of cardiac failure, 2000, Volume: 6, Issue:2 Suppl 1 Topics: Adrenergic beta-Agonists; Animals; Animals, Newborn; Apoptosis; Gene Expression Regulation; Heart Fa	2000
Factors affecting renal cortical blood flow. A review. Canadian journal of physiology and pharmacology, 1975, Volume: 53, Issue:1 Topics: Acetylcholine; Acute Kidney Injury; Angiotensin II; Animals; Bradykinin; Diuretics; Dogs; Dopamine;	1975
In vivo studies of myocardial beta-adrenergic receptor pharmacology in patients with congestive heart failure. Circulation, 1990, Volume: 82, Issue:2 Suppl Topics: Diastole; Exercise; Heart; Heart Failure; Heart Rate; Humans; Isoproterenol; Myocardial Contraction;	1990
Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure. The American journal of medicine, 1986, Feb-28, Volume: 80, Issue:2B Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Dogs;	1986
Early abnormalities in myocardial cell function in experimental diabetes. Acta pharmacologica et toxicologica, 1986, Volume: 59 Suppl 2 Topics: Adenosine Triphosphate; Adult; Animals; Blood Glucose; Calcium; Calcium-Transporting ATPases; Catech	1986
Practical considerations in the management of shock complicating acute myocardial infarction. A summary of current practice. The American journal of cardiology, 1970, Volume: 26, Issue:6 Topics: Acute Disease; Arrhythmias, Cardiac; Atropine; Blood Pressure Determination; Central Venous Pressure	1970
The failing myocardium. I. Drug management. The Medical clinics of North America, 1973, Volume: 57, Issue:1 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Atropine; Blood Pressure; Blood Volume; Cardiac Output; D	1973
Treatment of the cardiomyopathies. The American journal of cardiology, 1973, Sep-07, Volume: 32, Issue:3 Topics: Adrenergic beta-Antagonists; Alcoholism; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Blood	1973
The pathophysiology of congestive heart failure in infancy. Cardiovascular clinics, 1972, Volume: 4, Issue:3 Topics: Acid-Base Equilibrium; Arteriovenous Malformations; Blood Chemical Analysis; Blood Gas Analysis; Blo	1972
Congenital complete heart block: an international study of the natural history. Cardiovascular clinics, 1972, Volume: 4, Issue:3 Topics: Adams-Stokes Syndrome; Adolescent; Adult; Bradycardia; Cardiomegaly; Child; Child, Preschool; Digita	1972
[Beta-receptor-blocking agents and anesthesia]. Die Medizinische Welt, 1969, Aug-30, Volume: 35 Topics: Adrenal Gland Neoplasms; Anesthesia; Angina Pectoris; Arrhythmias, Cardiac; Asthma; Cardiomyopathy,	1969
New developments and therapeutic applications of cardiac stimulating agents. The American journal of cardiology, 1973, Sep-20, Volume: 32, Issue:4 Topics: Cardiac Output; Catecholamines; Digitalis Glycosides; Digitoxin; Digoxin; Dopamine; Glucagon; Heart;	1973
[Circulatory failure refractory to treatment]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1974, Jan-15, Volume: 27, Issue:2 Topics: Blood Transfusion; Digitalis Glycosides; Diuretics; Dopamine; Glucagon; Heart Failure; Humans; Isopr	1974
Propranolol. Disease-a-month : DM, 1974 Topics: Administration, Oral; Angina Pectoris; Arrhythmias, Cardiac; Asthma; Blood Pressure; Cardiac Output;	1974
[Pathological anatomy in heart insufficiency]. Arztliche Forschung, 1967, Feb-10, Volume: 21, Issue:2 Topics: Bronchodilator Agents; Dipyridamole; Endoplasmic Reticulum; Glycogen; Heart; Heart Failure; Humans;	1967
Use of sympathomimetic amines in heart failure. The American journal of cardiology, 1968, Volume: 22, Issue:2 Topics: Cardiac Glycosides; Dopamine; Epinephrine; Heart Failure; Hemodynamics; Humans; Isoproterenol; Natri	1968
[The function of the circulatory system]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1969, Jan-10, Volume: 58, Issue:1 Topics: Adult; Aminophylline; Angiocardiography; Animals; Blood Circulation; Blood Pressure; Brain Stem; Car	1969
Venous pressure and other thoughts. Proceedings of the Royal Society of Medicine, 1969, Jul-07, Volume: 62, Issue:7 Topics: Anesthesia; Blood Pressure; Blood Volume Determination; Cardiac Output; Catecholamines; Chlorpromazi	1969
Power failure in acute myocardial infarction. Progress in cardiovascular diseases, 1970, Volume: 12, Issue:6 Topics: Angiocardiography; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Assisted Circulation; Blood Pressur	1970
Management of arrhythmias in acute myocardial infarction. American family physician, 1971, Volume: 4, Issue:1 Topics: Acid-Base Equilibrium; Adams-Stokes Syndrome; Arrhythmias, Cardiac; Atropine; Bradycardia; Cardiac O	1971
Congestive heart failure in the infant. A functional approach. Pediatric clinics of North America, 1971, Volume: 18, Issue:4 Topics: Acid-Base Equilibrium; Arrhythmias, Cardiac; Blood Gas Analysis; Blood Glucose; Diagnosis, Different	1971

Article	Year
[Echocardiographic evaluation of left ventricular function during therapy with cardiovascularly effective drugs]. Zeitschrift fur Kardiologie, 1976, Volume: 65, Issue:8 Topics: Digoxin; Echocardiography; Heart; Heart Failure; Heart Ventricles; Humans; Isoproterenol; Propranolo	1976
Coronary perfusion versus cold ischemic arrest during aortic valve surgery. A randomized study. Circulation, 1974, Volume: 49, Issue:6 Topics: Adult; Aged; Aortic Valve; Arrhythmias, Cardiac; Cardiac Catheterization; Cardiac Output; Creatine K	1974
[Cardiac output, heart rate and stroke volume, blood pressure and peripheral circulatory resistance in dogs under the influence of physical work and the administration of catecholamines and atropine]. Archiv fur Kreislaufforschung, 1965, Volume: 48, Issue:1 Topics: Animals; Atropine; Blood Circulation; Blood Pressure; Cardiac Catheterization; Cardiac Output; Child	1965

isoproterenol and Heart Failure

Research Excerpts

Research

Studies (642)

Authors

Clinical Trials (4)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Sircar, I	1
Duell, BL	1
Bobowski, G	1
Bristol, JA	1
Evans, DB	1
Wang, Y	17
Zhang, X	5
Fu, Y	2
Fu, D	2
Zhen, D	3
Xing, A	1
Chen, Y	4
Gong, G	1
Wei, C	2
Flamant, M	1
Mougenot, N	2
Balse, E	1
Le Fèvre, L	1
Atassi, F	1
Gautier, EL	1
Le Goff, W	1
Keck, M	1
Nadaud, S	1
Combadière, C	1
Boissonnas, A	1
Pavoine, C	1
Na, RS	1
Bai, X	1
Fu, DN	1
Wei, CX	1
Liu, MJ	1
Yu, LJ	1
Gao, L	2
Li, T	2
Li, S	2
Song, Z	1
Chang, Y	1
Yuan, L	1
Feng, L	1
Li, G	2